CHI's Fifth Annual Recombinant Antibodies , Cambridge, MA, USA
Event Apr 28
The pipeline of therapeutic antibodies has been growing steadily, building on successful clinical trials, particularly in cancer. This growth will certainly accelerate, as genomic companies with many novel targets seek to employ antibodies to modulate these targets. In addition, studies employing antibodies, or antibody mimics, are being ramped up as part of the explosive growth of proteomics. All of these trends place a tremendous emphasis on the development of new approaches for faster antibody development, improved methods of selection and optimization, alternatives for production, and evaluation for novel applications. This conference will provide you with key updates on important developments in each of these areas.